Literature DB >> 14559793

Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.

Giovanna Cutrona1, Elisabetta M Carpaneto, Anna Ponzanelli, Massimo Ulivi, Enrico Millo, Sonia Scarfì, Silvio Roncella, Umberto Benatti, Lidia C Boffa, Manlio Ferrarini.   

Abstract

In Burkitt's Lymphoma there is an up-regulation of the c-myc oncogene caused by its translocation from chromosome 8 to chromosome 14, often close to the E mu enhancer of the immunoglobulin heavy chain locus (IgH). In Burkitt's Lymphoma cells, a peptide nucleic acid complementary for a specific unique E mu intronic sequence selectively blocked the expression of the c-myc oncogene under E mu control but not of other c-myc alleles. This Peptide Nucleic Acid also inhibited IgM expression in B cells. The finding that PNAs specific for a regulatory noncoding sequence can block gene expression has important conceptual and practical implications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14559793

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Targeting DNA G-quadruplex structures with peptide nucleic acids.

Authors:  Igor G Panyutin; Mykola I Onyshchenko; Ethan A Englund; Daniel H Appella; Ronald D Neumann
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Autorepression of Epstein-Barr virus nuclear antigen 1 expression by inhibition of pre-mRNA processing.

Authors:  Mikio Yoshioka; Michelle M Crum; Jeffery T Sample
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

Review 3.  Nanotechnology approaches for gene transfer.

Authors:  Karin E Lundin; Oscar E Simonson; Pedro M D Moreno; Eman M Zaghloul; Iulian I Oprea; Mathias G Svahn; C I Edvard Smith
Journal:  Genetica       Date:  2009-06-02       Impact factor: 1.082

4.  Obstruction of BRAFV600E transcription by complementary PNA oligomers as a means to inhibit BRAF-mutant melanoma growth.

Authors:  J H Rothman; O Surriga; E de Stanchina; S D Vasudeva; G K Schwartz
Journal:  Cancer Gene Ther       Date:  2017-09-22       Impact factor: 5.987

5.  Down-regulation of MDM2 and activation of p53 in human cancer cells by antisense 9-aminoacridine-PNA (peptide nucleic acid) conjugates.

Authors:  Takehiko Shiraishi; Peter E Nielsen
Journal:  Nucleic Acids Res       Date:  2004-09-15       Impact factor: 16.971

6.  Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice.

Authors:  Jianxia Guo; Robert A Parise; Erin Joseph; Merrill J Egorin; John S Lazo; Edward V Prochownik; Julie L Eiseman
Journal:  Cancer Chemother Pharmacol       Date:  2008-05-29       Impact factor: 3.333

7.  Inhibiting gene expression with peptide nucleic acid (PNA)--peptide conjugates that target chromosomal DNA.

Authors:  Jiaxin Hu; David R Corey
Journal:  Biochemistry       Date:  2007-05-31       Impact factor: 3.162

8.  Quadruplex formation is necessary for stable PNA invasion into duplex DNA of BCL2 promoter region.

Authors:  Mykola I Onyshchenko; Timur I Gaynutdinov; Ethan A Englund; Daniel H Appella; Ronald D Neumann; Igor G Panyutin
Journal:  Nucleic Acids Res       Date:  2011-05-18       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.